CO6801750A2 - Composición de complejo oral que contiene eter de ácido graso omega-3 e inhibidor de reductasa hmg-coa - Google Patents

Composición de complejo oral que contiene eter de ácido graso omega-3 e inhibidor de reductasa hmg-coa

Info

Publication number
CO6801750A2
CO6801750A2 CO13247569A CO13247569A CO6801750A2 CO 6801750 A2 CO6801750 A2 CO 6801750A2 CO 13247569 A CO13247569 A CO 13247569A CO 13247569 A CO13247569 A CO 13247569A CO 6801750 A2 CO6801750 A2 CO 6801750A2
Authority
CO
Colombia
Prior art keywords
hmg
composition
fatty acid
coa reductase
reductase inhibitor
Prior art date
Application number
CO13247569A
Other languages
English (en)
Inventor
Yong Ii Kim
Eun Jin Yoon
Ho Taek Im
Yoon Sub Shin
Jae Hyun Park
Jong Soo Woo
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47280992&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6801750(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of CO6801750A2 publication Critical patent/CO6801750A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CO13247569A 2011-03-23 2013-10-18 Composición de complejo oral que contiene eter de ácido graso omega-3 e inhibidor de reductasa hmg-coa CO6801750A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20110025940 2011-03-23
KR1020110041168A KR101310710B1 (ko) 2011-03-23 2011-04-29 오메가-3 지방산 에스테르 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 경구용 복합 조성물

Publications (1)

Publication Number Publication Date
CO6801750A2 true CO6801750A2 (es) 2013-11-29

Family

ID=47280992

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13247569A CO6801750A2 (es) 2011-03-23 2013-10-18 Composición de complejo oral que contiene eter de ácido graso omega-3 e inhibidor de reductasa hmg-coa

Country Status (31)

Country Link
US (1) US20140010872A1 (es)
EP (1) EP2688558B1 (es)
JP (1) JP2014508802A (es)
KR (1) KR101310710B1 (es)
CN (1) CN103442699B (es)
AR (1) AR085547A1 (es)
AU (1) AU2012231944B2 (es)
BR (1) BR112013023819A2 (es)
CA (1) CA2830342C (es)
CL (1) CL2013002611A1 (es)
CO (1) CO6801750A2 (es)
CR (1) CR20130491A (es)
DO (1) DOP2013000210A (es)
EA (1) EA023405B1 (es)
EC (1) ECSP13012959A (es)
ES (1) ES2550392T3 (es)
GT (1) GT201300217A (es)
HK (1) HK1189173A1 (es)
IL (1) IL228516A (es)
JO (1) JO3071B1 (es)
MA (1) MA35042B1 (es)
MX (1) MX343097B (es)
MY (1) MY157200A (es)
NI (1) NI201300086A (es)
PE (1) PE20140640A1 (es)
SA (1) SA112330374B1 (es)
SG (1) SG193491A1 (es)
TW (1) TWI571271B (es)
UA (1) UA106457C2 (es)
WO (1) WO2012128587A2 (es)
ZA (1) ZA201307871B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3578177A1 (en) 2008-09-02 2019-12-11 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
MX2011011538A (es) 2009-04-29 2012-06-13 Amarin Pharma Inc Composicion farmaceutica estable y metodos de uso de la misma.
KR101357438B1 (ko) 2009-04-29 2014-02-06 아마린 코포레이션 피엘씨 Ｅｐａ 및 심혈관 제제를 포함하는 제약 조성물 및 그의 사용 방법
NZ597193A (en) 2009-06-15 2014-01-31 Amarin Pharmaceuticals Ie Ltd Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
WO2011038122A1 (en) 2009-09-23 2011-03-31 Amarin Corporation Plc Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2012074930A2 (en) 2010-11-29 2012-06-07 Amarin Pharma, Inc. Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
AU2013207368A1 (en) 2012-01-06 2014-07-24 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject
SG10201913646PA (en) 2012-06-29 2020-03-30 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) * 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
GB2512098A (en) * 2013-03-20 2014-09-24 Roly Bufton An oral dosage form
WO2014182003A1 (en) * 2013-05-06 2014-11-13 Hanmi Pharm. Co., Ltd. Composite formulation comprising a film coating layer containing rosuvastatin or a pharmaceutically acceptable salt thereof
KR102240429B1 (ko) * 2013-05-06 2021-04-15 한미약품 주식회사 로수바스타틴 또는 이의 약학적으로 허용되는 염이 함유된 필름 코팅층을 포함하는 복합 제형
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
KR20160002411A (ko) * 2014-06-30 2016-01-07 한미약품 주식회사 5-α-환원효소 억제제-함유 필름 코팅층을 포함하는 복합제제 및 그 제조방법
WO2016003180A1 (ko) * 2014-06-30 2016-01-07 한미약품 주식회사 5-α-환원효소 억제제-함유 필름 코팅층을 포함하는 복합제제 및 그 제조방법
WO2016003181A1 (ko) * 2014-06-30 2016-01-07 한미약품 주식회사 활성성분-함유 필름 코팅층을 포함하는 복합제제
TWI525110B (zh) 2014-12-24 2016-03-11 財團法人工業技術研究院 聚合物、及包含其之醫藥組合物
KR101950907B1 (ko) * 2016-02-05 2019-02-21 한국유나이티드제약 주식회사 지용성 약물 및 방유성 기제가 코팅된 고형제제를 포함하는 경구용 복합제제
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2017171484A1 (ko) * 2016-03-31 2017-10-05 한미약품 주식회사 오메가-3 지방산 또는 이의 에스테르, 및 하이드록시메틸글루타릴 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제
TW201900160A (zh) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
FI4056176T3 (fi) 2018-09-24 2024-05-30 Amarin Pharmaceuticals Ie Ltd Menetelmät kardiovaskulaaristen tapahtumien riskin pienentämiseksi tutkittavassa
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9509764D0 (en) * 1995-05-15 1995-07-05 Tillotts Pharma Ag Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
AU3651102A (en) * 2000-11-29 2002-06-11 Smithkline Beecham Corp Composition containing statins and calcium for improved cardiovascular health
ITRM20040395A1 (it) * 2004-08-03 2004-11-03 Sigma Tau Ind Farmaceuti Composizione comprendente statine e acidi grassi omega 3.
ES2255426B1 (es) * 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
US20070191467A1 (en) * 2004-12-06 2007-08-16 Reliant Pharmaceutical, Inc. Statin and omega-3 fatty acids for lipid therapy
US20060211762A1 (en) * 2004-12-06 2006-09-21 Rongen Roelof M Omega-3 fatty acids and dyslipidemic agent for lipid therapy
CN101098690A (zh) * 2004-12-06 2008-01-02 瑞莱恩特医药品有限公司 用于血脂治疗的ω-3脂肪酸和脂血异常剂
WO2006096806A2 (en) * 2005-03-08 2006-09-14 Reliant Pharmaceutiacals, Inc. Treatment with statin and omega-3 fatty acids and a combination product thereof
CA2616806A1 (en) * 2005-07-28 2007-02-08 Reliant Pharmaceuticals, Inc. Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof
JP5628480B2 (ja) * 2006-03-09 2014-11-19 グラクソスミスクライン エルエルシー 医薬成分を含有するコーティングカプセル
US8784886B2 (en) * 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
US20090041839A1 (en) * 2007-05-23 2009-02-12 Beasley Martin W Pharmaceutical compositions for the treatment of pain
BRPI0822019A2 (pt) * 2008-01-10 2015-07-21 Takeda Pharmaceutical Cápsula sem costura
MX2010008940A (es) * 2008-02-13 2010-10-05 Bayer Schering Pharma Ag Sistemas de administracion de drogas que contienen estradiol.
KR20090091085A (ko) * 2008-02-22 2009-08-26 한올제약주식회사 방출성이 제어된 약제학적 제제
KR20090114190A (ko) * 2008-04-29 2009-11-03 한올제약주식회사 방출성이 제어된 ＨＭＧ―ＣｏＡ 환원 효소 억제제와안지오텐신―Ⅱ―수용체 차단제의 복합 조성물
ITFI20080243A1 (it) * 2008-12-15 2010-06-16 Valpharma Sa Formulazioni per la somministrazione orale di acidi grassi omega polienoici in combinazione con statine di origine naturale o semi-sintetica.

Also Published As

Publication number Publication date
DOP2013000210A (es) 2014-01-31
JP2014508802A (ja) 2014-04-10
EP2688558B1 (en) 2015-10-14
MY157200A (en) 2016-05-13
NI201300086A (es) 2014-05-05
AU2012231944A1 (en) 2013-05-02
EA023405B1 (ru) 2016-05-31
CN103442699A (zh) 2013-12-11
UA106457C2 (ru) 2014-08-26
TWI571271B (zh) 2017-02-21
ES2550392T3 (es) 2015-11-06
ZA201307871B (en) 2015-01-28
SA112330374B1 (ar) 2015-01-08
IL228516A0 (en) 2013-12-31
NZ616907A (en) 2016-02-26
GT201300217A (es) 2014-12-30
CR20130491A (es) 2013-10-22
WO2012128587A3 (en) 2012-11-15
MA35042B1 (fr) 2014-04-03
CA2830342C (en) 2016-01-19
KR20120109950A (ko) 2012-10-09
TW201249483A (en) 2012-12-16
CA2830342A1 (en) 2012-09-27
MX2013010753A (es) 2013-10-17
EP2688558A4 (en) 2014-09-24
EA201391372A1 (ru) 2014-01-30
JO3071B1 (ar) 2017-03-15
BR112013023819A2 (pt) 2016-12-13
HK1189173A1 (en) 2014-05-30
EP2688558A2 (en) 2014-01-29
WO2012128587A2 (en) 2012-09-27
KR101310710B1 (ko) 2013-09-27
PE20140640A1 (es) 2014-06-11
US20140010872A1 (en) 2014-01-09
CN103442699B (zh) 2015-07-01
AU2012231944B2 (en) 2015-08-27
MX343097B (es) 2016-10-25
AR085547A1 (es) 2013-10-09
CL2013002611A1 (es) 2014-07-11
ECSP13012959A (es) 2013-11-29
SG193491A1 (en) 2013-10-30
IL228516A (en) 2017-12-31

Similar Documents

Publication Publication Date Title
CO6801750A2 (es) Composición de complejo oral que contiene eter de ácido graso omega-3 e inhibidor de reductasa hmg-coa
EP2844257A4 (en) Fatty Acid Conjugates from Statin and FXR Agonists; COMPOSITIONS AND METHODS OF USE
HK1206248A1 (en) Compositions of statins and omega-3 fatty acids -3
SMT201600021B (it) Nuovi composti di chinolina sostituiti come inibitori della s-nitrosoglutatione reduttasi
CO6801786A2 (es) Ésteres grasos alcoxilados de la metátesis de aceites naturales y sus derivados
BR112013018877A2 (pt) composições farmacêuticas que compreendem anticorpos humanos para pcsk9
SG10201800243XA (en) SELF-EMULSIFYING COMPOSITION OF ω-3 FATTY ACID
BR112012017831A2 (pt) micro-organismos produtores de ácido eicosapentaenóico, composições e ácido graxo e método de fabricação e uso dos mesmos
ZA201202263B (en) Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
EP2585587A4 (en) ACYLE REDUCTASES FORMING FATTY ALCOHOLS (FAR) AND METHODS OF USING SAME
CL2014002911A1 (es) Anticuerpo anti-gcc; metodo de produccion; kit que lo contiene y usos
DK2575787T3 (da) Farmaceutiske formuleringer af statiner og omega-3-fedtsyrer til indkapsling
EP2917358A4 (en) COMPOSITIONS AND METHODS FOR THE BIOLOGICAL PRODUCTION OF FATTY ACID DERIVATIVES
EP2560633B8 (en) Intravenous omega-3 fatty acid compositions & method of use
BR112013010331A2 (pt) composições adesivas crepadas e métodos de uso dessas composições
EP2785852A4 (en) COMPOSITIONS COMPRISING FATTY ACIDS CONTAINING CARBON ATOMS AND METHODS OF PREPARATION AND USE THEREOF
EP2619194A4 (en) CATECHIN FATTY ACID DERIVATIVES AND METHODS OF USE
EP2794884A4 (en) FAT ALCOHOL PRODUCED ACYL REDUCTASE (VARIANTS) AND METHOD OF USE THEREOF
CO6890096A2 (es) Método para la prueba de disolución de composiciones sólidas que contienen enzimas digestivas
CL2015001051A1 (es) Composición de microemulsión de aceite/acido graso
CR20130375A (es) Preparaciones que contienen antraquinona/formulaciones de lignina
IT1403611B1 (it) Composizione di poliesteri
BR112014028301A2 (pt) uso de um ácido de tal óleo que é modificado por saponificação
HK1199396A1 (en) Oral complex formulation comprising omega-3 fatty acid and hmg-coa reductase inhibitor with improved stability -3 hmg-coa
BR112014015225A8 (pt) novo éster de ácido graxo, novo emoliente, e, uso de um éster de ácido graxo

Legal Events

Date Code Title Description
FC Application refused